Compare
IB Acquisition Corp. vs bioAffinity Technologies, Inc. vs iSpecimen Inc. vs Foxo Technologies Inc.
| Latest fiscal year | IB Acquisition Corp. IBAC | bioAffinity Technologies, Inc. BIAF | iSpecimen Inc. ISPC | Foxo Technologies Inc. FOXO |
|---|---|---|---|---|
| Year ended | 2025-09-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $6.16M | $1.93M | $16.37M |
| Revenue growth (YoY) | n/a | -34.2% | -79.2% | +304.0% |
| Gross margin | n/a | n/a | 1.2% (computed) | n/a |
| Operating margin | n/a | -171.6% | -465.4% | -63.1% |
| Net margin | n/a | -242.0% | -543.7% | -75.9% |
| Net income | $3.42M | -$14.91M | -$10.49M | -$12.43M |
| EPS (Diluted) | n/a | -$8.66 | -$2.28 | n/a |
| Operating cash flow | -$1.32M | -$9.33M | -$4.24M | -$3.87M |
| Free cash flow | n/a | -$9.39M | -$4.24M | -$3.93M |
| Cash & equivalents | $428.7K | $6.45M | $6.88M | $207.5K |
| Total assets | $17.13M | $10.96M | $9.53M | $44.58M |
| Total liabilities | $1.83M | $3.68M | $6.44M | $33.50M |
| Shareholders' equity | -$681.3K | $7.28M | $3.09M | $11.14M |
| Return on year-end equity | n/a | -204.9% | -339.6% | -111.5% |
| Shares outstanding | 4.25M | 4.50M | 8.48M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | IB Acquisition Corp. | bioAffinity Technologies, Inc. | iSpecimen Inc. | Foxo Technologies Inc. |
|---|---|---|---|---|
| Latest | n/a | $6.16M Ended 2025-12-31 | $1.93M Ended 2025-12-31 | $16.37M Ended 2025-12-31 |
| 1 year earlier | n/a | $9.36M Ended 2024-12-31 | $9.29M Ended 2024-12-31 | $4.05M Ended 2024-12-31 |
| 2 years earlier | n/a | $2.53M Ended 2023-12-31 | $9.93M Ended 2023-12-31 | $145.3K Ended 2023-12-31 |
| 3 years earlier | n/a | $6.90M Ended 2022-12-31 | $10.40M Ended 2022-12-31 | $511.0K Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $11.14M Ended 2021-12-31 | $120.0K Ended 2021-12-31 |